Banco Santander S.A. (SAN) – Business Wire
-
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
-
Santander US Survey Finds Optimism Rising Among Middle-Income Households as Concerns about Inflation and Recession Ease
-
Santander Names Swati Bhatia Head of Retail Banking and Transformation
-
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
-
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
-
Santander US Middle-Income Survey Finds Majority of Americans Remained Optimistic in 2023, See Headwinds Ahead in 2024
-
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
-
Santander Closes on Transaction with the FDIC to Service Signature Bank's Multifamily Real Estate Assets
-
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
-
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
-
Santander Bank Introduces New Essential Checking Account
-
Santander US Paths to Prosperity Research Finds Consumers Resilient Though Pressures Mounting
-
Santander Bank Unifies U.S. Commercial Businesses, Names Michael Lee Head of Commercial Banking
-
GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
-
Sanofi Bridging the Gap between the Homeless and Society via Futsal
-
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
-
Santander Bank Raises Its Prime Rate to 8.50%
-
Santander US Research Finds Consumers Resilient Despite Uncertainty
-
Santander Signs Jon Rahm as New Global Ambassador
-
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
-
Santander US Releases 2022 Prosperity with Purpose Report
-
Santander US Unveils New Community Plan
-
Santander Bank Raises Its Prime Rate to 8.25%
-
Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
-
Sanofi Announces Launch of AVAXIM® Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
-
Santander US Research Reveals Middle-Income Americans Are Optimistic about Achieving Financial Prosperity
-
Santander US Research Reveals Middle-Income Americans Are Optimistic about Achieving Financial Prosperity
-
Santander Bank Raises Its Prime Rate to 8.0%
-
Santander Bank Raises Its Prime Rate to 7.75%
-
Bruce Jackson Is Named Head of the Santander US Auto Business and CEO of Santander Consumer
-
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
-
Santander US Cultivate Small Business Program Completes Sixth Cohort with $300,000 in Grants to Entrepreneurs
-
Santander Bank Raises Its Prime Rate to 7.50%
-
Santander Bank Offering Healthcare Equipment Financing as Part of Commercial Finance Expansion
-
Santander Commercial Banking Appoints Two New Leaders
-
Santander Bank Raises Its Prime Rate to 7.00%
-
Santander Bank Enhances Safety Net, Further Reduces Overdraft Fees for Every Client
-
Santander US Issues Inaugural $500 Million Sustainability Notes Under Newly Released Sustainability Funding Global Framework
-
Santander Bank Raises Its Prime Rate to 6.25%
-
Santander US Teams Up with City Year and Rafael Nadal to Support Students
-
Apex Clean Energy Secures Financing for 224 MW Great Pathfinder Wind
-
NIHR and Sanofi Announce First Patient Enrolled in Large European Clinical Study to Investigate Protection Against RSV, the Leading Cause of Infant Hospitalisation Worldwide
-
Santander US Releases Environmental, Social and Governance Report
-
Apex Clean Energy Accelerates Transition to IPP Through Refinancing
-
Santander Bank Raises Its Prime Rate to 5.50%
-
Santander Holdings USA, Inc. Provides Statement on Supervisory Stress Test Results
-
Santander Bank Raises Its Prime Rate to 4.75%
-
Santander Bank Opens New Branch on Boylston Street in Boston
-
Santander Bank Raises Its Prime Rate to 4.00%
-
Santander Bank Continues to Digitize Solutions with Launch of the Santander eLockBox
Back to SAN Stock Lookup
